Cannabinoids in Pancreatic Cancer: Correlation with Survival and Pain

Overview

Journal Int J Cancer

Specialty Oncology

Date 2007 Oct 19

PMID 17943729

Citations 67

Authors

Christoph W Michalski

Florian E Oti

Mert Erkan

Danguole Sauliunaite

Frank Bergmann

Pal Pacher

Sandor Batkai

Michael W Muller

Nathalia A Giese

Helmut Friess

Jorg Kleeff

Affiliations

Soon will be listed here.

Abstract

Cannabinoids exert antiproliferative properties in a variety of malignant tumors, including pancreatic ductal adenocarcinoma (PDAC). In our study, we quantitatively evaluated the immunoreactivity for cannabinoid-1 (CB1) and cannabinoid-2 (CB2) receptors as well as for the endocannabinoid metabolizing enzymes fatty acid amide hydrolase (FAAH) and monoacyl glycerol lipase (MGLL). Furthermore, quantitative real-time RT-PCR for CB1, CB2, FAAH and MGLL in normal pancreas and pancreatic cancer tissues was performed. Levels of endocannabinoids were determined by liquid chromatography/mass spectrometry. Immunoreactivity scores and QRT-PCR expression levels were correlated with the clinico-pathological (TNM, survival, pain) status of the patients. Evaluation of endocannabinoid levels revealed that these remained unchanged in PDAC compared to the normal pancreas. Patients with high CB1 receptor levels in enlarged nerves in PDAC had a lower combined pain score (intensity, frequency, duration; p = 0.012). There was a significant relationship between low CB1 receptor immunoreactivity or mRNA expression levels (p = 0.0011 and p = 0.026, respectively), or high FAAH and MGLL cancer cell immunoreactivity (p = 0.036 and p = 0.017, respectively) and longer survival of PDAC patients. These results are underlined by a significant correlation of high pain scores and increased survival (p = 0.0343). CB2 receptor immunoreactivity, CB2 receptor, FAAH and MGLL mRNA expression levels did not correlate with survival. Therefore, changes in the levels of endocannabinoid metabolizing enzymes and cannabinoid receptors on pancreatic cancer cells may affect prognosis and pain status of PDAC patients.

Citing Articles

Spatial Transcriptomics Reveals Novel Mechanisms Involved in Perineural Invasion in Pancreatic Ductal Adenocarcinomas.

Lakis V, Chan N, Lyons R, Blackburn N, Nguyen T, Chang C Cancers (Basel). 2025; 17(5).

PMID: 40075699 PMC: 11899704. DOI: 10.3390/cancers17050852.

Development of a prognostic model for early-stage gastric cancer-related DNA methylation-driven genes and analysis of immune landscape.

Su C, Lin Z, Ye Z, Liang J, Yu R, Wan Z Front Mol Biosci. 2024; 11:1455890.

PMID: 39575189 PMC: 11579923. DOI: 10.3389/fmolb.2024.1455890.

Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity Focused Ultrasound in Combination with Palliative Chemotherapy in Inoperable Pancreatic....

Marinova M, Khouri D, Kuppers J, Ramig O, Strunk H, Breuers J J Clin Med. 2024; 13(13).

PMID: 38999283 PMC: 11242276. DOI: 10.3390/jcm13133717.

A comprehensive review on phytochemicals in the treatment and prevention of pancreatic cancer: Focusing on their mechanism of action.

Arnab M, Islam M, Saydur Rahman M Health Sci Rep. 2024; 7(5):e2085.

PMID: 38690008 PMC: 11056788. DOI: 10.1002/hsr2.2085.

Anti-proliferative and apoptotic effect of cannabinoids on human pancreatic ductal adenocarcinoma xenograft in BALB/c nude mice model.

Le T, Meesiripan N, Sanggrajang S, Suwanpidokkul N, Prayakprom P, Bodhibukkana C Sci Rep. 2024; 14(1):6515.

PMID: 38499634 PMC: 10948389. DOI: 10.1038/s41598-024-55307-y.

References

Di Marzo V, Bifulco M, De Petrocellis L . The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004; 3(9):771-84. DOI: 10.1038/nrd1495. View

Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G . Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006; 66(13):6748-55. DOI: 10.1158/0008-5472.CAN-06-0169. View

Hart S, Fischer O, Ullrich A . Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004; 64(6):1943-50. DOI: 10.1158/0008-5472.can-03-3720. View

Nithipatikom K, Endsley M, Isbell M, Falck J, Iwamoto Y, Hillard C . 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004; 64(24):8826-30. DOI: 10.1158/0008-5472.CAN-04-3136. View

Ligresti A, Cascio M, Di Marzo V . Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Disord. 2005; 4(6):615-23. DOI: 10.2174/156800705774933104. View

Walker J, Strangman N, Huang S . Cannabinoids and pain. Pain Res Manag. 2002; 6(2):74-9. DOI: 10.1155/2001/413641. View

Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W . Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the.... J Clin Oncol. 2006; 24(21):3394-400. DOI: 10.1200/JCO.2005.05.1847. View

Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, Giroux V . The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell. 2006; 9(4):301-12. DOI: 10.1016/j.ccr.2006.03.005. View

Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V . A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 2004; 18(13):1606-8. DOI: 10.1096/fj.04-1754fje. View

10.

Galve-Roperh I, Sanchez C, Cortes M, Gomez Del Pulgar T, Izquierdo M, Guzman M . Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000; 6(3):313-9. DOI: 10.1038/73171. View

11.

Giang D, Cravatt B . Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A. 1997; 94(6):2238-42. PMC: 20071. DOI: 10.1073/pnas.94.6.2238. View

12.

De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M . The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A. 1998; 95(14):8375-80. PMC: 20983. DOI: 10.1073/pnas.95.14.8375. View

13.

Sarfaraz S, Afaq F, Adhami V, Mukhtar H . Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005; 65(5):1635-41. DOI: 10.1158/0008-5472.CAN-04-3410. View

14.

Sener S, Fremgen A, Menck H, WINCHESTER D . Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999; 189(1):1-7. DOI: 10.1016/s1072-7515(99)00075-7. View

15.

Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D . Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol. 2005; 144(8):1032-6. PMC: 1576089. DOI: 10.1038/sj.bjp.0706134. View

16.

Matsuda L, Lolait S, Brownstein M, Young A, Bonner T . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346(6284):561-4. DOI: 10.1038/346561a0. View

17.

Fogli S, Nieri P, Chicca A, Adinolfi B, Mariotti V, Iacopetti P . Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett. 2006; 580(7):1733-9. DOI: 10.1016/j.febslet.2006.02.024. View

18.

Munro S, Thomas K . Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365(6441):61-5. DOI: 10.1038/365061a0. View

19.

Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler M . Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene. 2005; 24(27):4421-32. DOI: 10.1038/sj.onc.1208642. View

20.

Guzman M, Duarte M, Blazquez C, RAVINA J, Rosa M, Galve-Roperh I . A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006; 95(2):197-203. PMC: 2360617. DOI: 10.1038/sj.bjc.6603236. View